secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2024-09-24T23:59:59+00:00
Accession:  0001493152-24-037958
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma enters $900K biomarker agreement with PreCheck for ENV105 trials
------------------------------------------------------------------------------

- Agreement with PreCheck Health Services for biomarker screening in ongoing lung (NCT05401110) and prostate (NCT05534646) cancer trials.
- Kairos to pay $900,000 for PreCheck's lab services using SolidTumorCheck+ platform.
- PreCheck will develop a companion diagnostic (three-gene PCR) for ENV105 to identify responsive patients.
- Target indications: EGFR-driven lung cancer resistant to osimertinib and castrate-resistant prostate cancer.
- Companion diagnostic to be submitted for FDA approval to guide Phase 3 patient selection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224037958/0001493152-24-037958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224037958/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-037958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer